Skip to main content

Advertisement

SpringerLink
Log in

The Interaction Between Neuroinflammation and β-Amyloid in Cognitive Decline in Parkinson’s Disease

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Activated microglia have been reported to play an important role in Parkinson’s disease (PD). A more rapid cognitive decline has been associated with deposits of β-amyloid. In this study, the aim was to evaluate the role of brain β-amyloid and its relationship with activated microglia in PD patients with normal and impaired cognition. We studied 17 PD patients with normal cognition (PDn), 12 PD patients with mild cognitive impairment (PD-MCI), and 12 healthy controls (HCs) with [11C] Pittsburgh compound B (PIB) to assess the impact of β-amyloid deposition in the brain on microglial activation evaluated using the translocator protein 18-kDa (TSPO) radioligand [18F]-FEPPA. [11C] PIB distribution volume ratio was measured in cortical and subcortical regions. [18F]-FEPPA total distribution volume values were compared for each brain region between groups to evaluate the effect of PIB positivity while adjusting for the TSPO rs6971 polymorphism. Factorial analysis of variance revealed a significant main effect of PIB positivity in the frontal lobe (F(1, 34) = 7.1, p = 0.012). Besides the frontal (p = 0.006) and temporal lobe (p = 0.001), the striatum (p = 0.018), the precuneus (p = 0.019), and the dorsolateral prefrontal cortex (p = 0.010) showed significant group × PIB positivity interaction effects. In these regions, PD-MCIs had significantly higher FEPPA VT if PIB-positive. Our results indicate an interaction between amyloid-β deposition and microglial activation in PD. Further investigations are necessary to evaluate if amyloid deposits cause neuroinflammation and further neurodegeneration or if increased microglia activation develops as a protective response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Chaudhuri KR, Healy DG, Schapira AHV, National Institute for Clinical Excellence (2006) Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5:235–245 http://linkinghub.elsevier.com/retrieve/pii/S1474442206703738. Accessed November 4, 2018

    Article  Google Scholar 

  2. Petrou M, Dwamena BA, Foerster BR, MacEachern MP, Bohnen NI, Müller MLTM, Albin RL, Frey KA (2015) Amyloid deposition in Parkinson’s disease and cognitive impairment: a systematic review. Mov Disord 30:928–935

    Article  CAS  Google Scholar 

  3. Imamura K, Hishikawa N, Sawada M et al (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol 106:518–526 http://link.springer.com/10.1007/s00401-003-0766-2. Accessed November 4, 2018

    Article  CAS  Google Scholar 

  4. Suridjan I, Pollock BG, Verhoeff NPLG, Voineskos AN, Chow T, Rusjan PM, Lobaugh NJ, Houle S et al (2015) In-vivo imaging of grey and white matter neuroinflammation in Alzheimer’s disease: a positron emission tomography study with a novel radioligand, “18 F”-FEPPA. Mol Psychiatry 20:1579–1587

    Article  CAS  Google Scholar 

  5. Edison P, Ahmed I, Fan Z et al (2013) Microglia, amyloid, and glucose metabolism in Parkinson’s disease with and without dementia. Neuropsychopharmacology 38:938–949 http://www.nature.com/articles/npp2012255. Accessed November 4, 2018

    Article  CAS  Google Scholar 

  6. Masters CL, Simms G, Weinman NA et al (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82:4245–4249 http://www.ncbi.nlm.nih.gov/pubmed/3159021. Accessed November 4, 2018

    Article  CAS  Google Scholar 

  7. Mastaglia FL, Johnsen RD, Byrnes ML et al (2003) Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson’s disease. Mov Disord 18:81–86 http://doi.wiley.com/10.1002/mds.10295. Accessed November 4, 2018

    Article  Google Scholar 

  8. Petrou M, Bohnen NI, Muller MLTM et al (2012) Abeta-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 79:1161–1167 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3525303&tool=pmcentrez&rendertype=abstract

    Article  CAS  Google Scholar 

  9. Mielke MM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Roberts RO, Geda YE, Swenson-Dravis DM et al (2012) Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology. 79:1570–1577

    Article  CAS  Google Scholar 

  10. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O'Keefe G et al (2008) Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79:1331–1338

    Article  CAS  Google Scholar 

  11. Gomperts SN, Locascio JJ, Rentz D et al (2013) Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 80:85–91 7p. Accessed at: http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108089057&site=ehost-live

    Article  Google Scholar 

  12. Prokop S, Miller KR, Heppner FL (2013) Microglia actions in Alzheimer’s disease. Acta Neuropathol 126:461–477 http://www.ncbi.nlm.nih.gov/pubmed/24224195. Accessed November 4, 2018

    Article  CAS  Google Scholar 

  13. Litvan I, Goldman JG, Tröster AI et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27:349–356 http://doi.wiley.com/10.1002/mds.24893. Accessed October 1, 2018

    Article  Google Scholar 

  14. Wilson AA, Garcia A, Parkes J et al (2008) Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol 35:305–314 http://linkinghub.elsevier.com/retrieve/pii/S0969805108000073. Accessed November 4, 2018

    Article  CAS  Google Scholar 

  15. Mathis CA, Bacskai BJ, Kajdasz ST et al (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12:295–298 http://www.ncbi.nlm.nih.gov/pubmed/11814781. Accessed November 4, 2018

    Article  CAS  Google Scholar 

  16. Rusjan PM, Wilson AA, Bloomfield PM, Vitcu I, Meyer JH, Houle S, Mizrahi R (2011) Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab 31:1807–1816 http://journals.sagepub.com/doi/10.1038/jcbfm.2011.55. Accessed October 1, 2018

    Article  CAS  Google Scholar 

  17. Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F, Tetsuya S, Houle S et al (2006) An automated method for the extraction of regional data from PET images. Psychiatry Res - Neuroimaging 147:79–89

    Article  Google Scholar 

  18. Bencherif B, Stumpf MJ, Links JM et al (2004) Application of MRI-based partial-volume correction to the analysis of PET images of mu-opioid receptors using statistical parametric mapping. J Nucl Med 45:402–408 http://www.ncbi.nlm.nih.gov/pubmed/15001679. Accessed November 4, 2018

    CAS  PubMed  Google Scholar 

  19. Lopresti BJ, Klunk WE, Mathis CA et al (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46:1959–1972 http://www.ncbi.nlm.nih.gov/pubmed/16330558. Accessed October 1, 2018

    CAS  PubMed  Google Scholar 

  20. Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, la Joie R, Arthur-Bentil SK et al (2015) Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 138:2020–2033

    Article  Google Scholar 

  21. Villemagne VL, Pike KE, Chételat G et al (2011) Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 69:181–192 http://doi.wiley.com/10.1002/ana.22248. Accessed October 1, 2018

    Article  CAS  Google Scholar 

  22. Lahiri DK, Nurnberger JI (1991) A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 19:5444 http://www.ncbi.nlm.nih.gov/pubmed/1681511. Accessed November 4, 2018

    Article  CAS  Google Scholar 

  23. Mizrahi R, Rusjan PM, Kennedy J, Pollock B, Mulsant B, Suridjan I, de Luca V, Wilson AA et al (2012) Translocator protein (18 kDa) polymorphism (rs6971) explains in-vivo brain binding affinity of the PET radioligand [18F]-FEPPA. J Cereb Blood Flow Metab 32:968–972

    Article  CAS  Google Scholar 

  24. Alvarez-Erviti L, Couch Y, Richardson J et al (2011) Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res 69:337–342 http://linkinghub.elsevier.com/retrieve/pii/S0168010211000101. Accessed November 4, 2018

    Article  CAS  Google Scholar 

  25. Akhtar RS, Xie SX, Chen YJ, Rick J, Gross RG, Nasrallah IM, van Deerlin VM, Trojanowski JQ et al (2017) Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS One 12:1–18. https://doi.org/10.1371/journal.pone.0177924

    Article  CAS  Google Scholar 

  26. Fan Z, Aman Y, Ahmed I et al (2015) Influence of microglial activation on neuronal function in Alzheimer’s and Parkinson’s disease dementia. Alzheimers Dement 11:608–21.e7 https://linkinghub.elsevier.com/retrieve/pii/S1552526014025011. Accessed November 4, 2018

    Article  Google Scholar 

  27. Gerhard A, Pavese N, Hotton G et al (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21:404–412 http://linkinghub.elsevier.com/retrieve/pii/S0969996105002263. Accessed November 4, 2018

    Article  CAS  Google Scholar 

  28. Kobylecki C, Counsell SJ, Cabanel N et al (2013) Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. Parkinsonism Relat Disord 19:527–532 https://linkinghub.elsevier.com/retrieve/pii/S1353802013000527. Accessed November 4, 2018

    Article  Google Scholar 

  29. Cai Z, Hussain MD, Yan LJ (2014) Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease. Int J Neurosci 124:307–321

    Article  CAS  Google Scholar 

  30. Hamelin L, Lagarde J, Dorothée G, Leroy C, Labit M, Comley RA, de Souza LC, Corne H et al (2016) Early and protective microglial activation in Alzheimer’s disease: a prospective study using18F-DPA-714 PET imaging. Brain. 139:1252–1264

    Article  Google Scholar 

  31. Lavisse S, Guillermier M, Hérard A-S et al (2012) Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci 32:10809–10818 http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.1487-12.2012. Accessed November 4, 2018

    Article  CAS  Google Scholar 

  32. Stokholm MG, Iranzo A, Østergaard K et al (2017) Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol 16:789–796 https://linkinghub.elsevier.com/retrieve/pii/S1474442217301734. Accessed November 4, 2018

    Article  Google Scholar 

  33. Stokholm MG, Iranzo A, Østergaard K et al (2018) Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. Neurobiol Dis 115:9–16 https://linkinghub.elsevier.com/retrieve/pii/S0969996118300494. Accessed November 4, 2018

    Article  CAS  Google Scholar 

  34. Jucaite A, Svenningsson P, Rinne JO, Cselényi Z, Varnäs K, Johnström P, Amini N, Kirjavainen A et al (2015) Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease. Brain 138:2687–2700 https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awv184. Accessed November 4, 2018

    Article  Google Scholar 

Download references

Funding

This study was supported by the National Parkinson Foundation and the Canadian Institutes of Health Research (MOP-136778). Antonio Strafella is supported also by the Canada Research Chair program from the Canadian Institutes of Health Research. Dr. Strafella has received honoraria from GE Healthcare Canada.

Author information

Authors and Affiliations

  1. Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada

    Christine Ghadery, Yuko Koshimori, Leigh Christopher, Jinhee Kim, Pablo Rusjan, Sylvain Houle & Antonio P. Strafella

  2. Krembil Research Institute, University Health Network (UHN), University of Toronto, Toronto, Ontario, Canada

    Christine Ghadery, Yuko Koshimori, Leigh Christopher, Jinhee Kim, Anthony E. Lang & Antonio P. Strafella

  3. E.J. Safra Parkinson Disease Program & Morton and Gloria Shulman Movement Disorder Unit, Neurology Division, Department of Medicine, Toronto Western Hospital, UHN, University of Toronto, 399 Bathurst Street, MCL 7-417, Toronto, Ontario, M5T 2S8, Canada

    Anthony E. Lang & Antonio P. Strafella

Authors
  1. Christine Ghadery
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuko Koshimori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leigh Christopher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jinhee Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pablo Rusjan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anthony E. Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sylvain Houle
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Antonio P. Strafella
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Christine Ghadery: acquisition of data, analysis and interpretation of data, and drafting of the manuscript. Yuko Koshimori: acquisition of data and critical revision of the manuscript for intellectual content. Leigh Christopher: acquisition of data and critical revision of the manuscript for intellectual content. Jinhee Kim: analysis and interpretation of data and critical revision of the manuscript for intellectual content. Pablo Rusjan: methodological PET supervision of data analyses and critical revision of the manuscript for intellectual content. Anthony E. Lang: critical revision of the manuscript for intellectual content. Sylvain Houle: critical revision of the manuscript for intellectual content. Antonio P. Strafella: study concept and design, critical revision of the manuscript for intellectual content, acquisition of funding, and overall study supervision.

Corresponding author

Correspondence to Antonio P. Strafella.

Ethics declarations

Conflict of Interest

The authors declared that they have no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghadery, C., Koshimori, Y., Christopher, L. et al. The Interaction Between Neuroinflammation and β-Amyloid in Cognitive Decline in Parkinson’s Disease. Mol Neurobiol 57, 492–501 (2020). https://doi.org/10.1007/s12035-019-01714-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-019-01714-6

Keywords

Search

Navigation